- Direction
- Inflecting
- Own history
- —
- Peers
- 69th
- Persistence
- REVERSING
· Pharmaceutical Preparations
RESEARCH SNAPSHOTREGENERON PHARMACEUTICALS, INC.'s latest supported as-filed period reports revenue of $5.1B. Every value below links to its SEC accession and metric lineage.
No material rule-based research observation currently meets GrossPattern's Insight value threshold. Current state, direction, and filing evidence remain available below.
Separate current dimensions—not a universal score or investment ranking.
A multidimensional view of the latest comparable filing—not a composite score or recommendation.
Level · gp.fundamentals.capex_revenue_ratio
Raw value 5.87% · OPTIONAL
Ratio · gp.fundamentals.operating_cash_flow + gp.fundamentals.revenue
Raw value 34.86% · OPTIONAL
Yoy · gp.fundamentals.revenue
Raw value 36.27% · CORE
Level · gp.fundamentals.inventory_revenue_ratio
Raw value 56.58% · OPTIONAL
Level · gp.fundamentals.operating_margin
Raw value 40.04% · CORE
Ratio · gp.fundamentals.rnd + gp.fundamentals.revenue
Raw value 35.08% · OPTIONAL
Level · gp.fundamentals.sbc_revenue_ratio
Business direction, financial quality, capital allocation, and governance evidence remain separate—never collapsed into a recommendation score.
Interpretation boundary Direction describes measurable company fundamentals. Governance reports observable evidence only; it does not grade management character or predict stock returns.
Latest available comparable states within 180 days, normalized with robust median/MAD statistics.
The most important deterministic changes, ranked by magnitude, issuer history, persistence, and accounting profile.
This cluster groups 3 independently calculated changes: Revenue increased 36.3%; Operating margin moved 1269 bp higher; Operating income increased 99.5%.
3 evidence-backed componentsThis cluster groups 2 independently calculated changes: Cash & equivalents increased 46.0%; Operating cash flow increased 10.2%.
2 evidence-backed componentsThis cluster groups 3 independently calculated changes: Revenue increased 16.7%; Operating margin moved 78 bp higher; Operating income increased 19.8%.
3 evidence-backed componentsThis cluster groups 2 independently calculated changes: Capital expenditure increased 49.1%; Capex / revenue moved 50 bp higher.
2 evidence-backed componentsCurrent liabilities changed +50.8% from the comparable as-filed period. The change ranks at the 100th percentile of 4 prior comparable changes.
Each point keeps the date investors could first observe it and its accession.
REGN · as filed with the SEC · reported-date aware
Direct SEC links, filing dates, report periods, and amendment flags.
0000872589-26-000034SEC ↗8-KOct 30, 2026Period Oct 30, 20260000872589-26-000032SEC ↗4Oct 15, 2026Period Oct 13, 20260001796226-26-000002SEC ↗8-KOct 6, 2026Period Oct 1, 20260001104659-26-113895SEC ↗8-KSep 30, 2026Period Sep 24, 20260001104659-26-112340SEC ↗4Sep 3, 2026Period Sep 2, 20260001663758-26-000002SEC ↗4Sep 3, 2026Period Sep 2, 20260001992352-26-000007SEC ↗Transaction semantics distinguish purchases, sales, awards, exercises, withholding, and derivatives.
| Filed / transacted | Reporting owner | Semantics | Shares | Price | Notional | Source |
|---|---|---|---|---|---|---|
| Oct 14, 2026Filed Oct 15, 2026 | MURPHY ANDREW JCo-Chief Scientific Officer | Open Market SaleDirect | 6 | $754 | $4,523 | Form 4 ↗ |
| Oct 14, 2026Filed Oct 15, 2026 | MURPHY ANDREW JCo-Chief Scientific Officer | Open Market SaleDirect | 35 | $756 | $26,457 | Form 4 ↗ |
| Oct 14, 2026Filed Oct 15, 2026 | MURPHY ANDREW JCo-Chief Scientific Officer | Open Market SaleDirect | 16 | $758 | $12,123 | Form 4 ↗ |
| Oct 14, 2026Filed Oct 15, 2026 | MURPHY ANDREW JCo-Chief Scientific Officer | Open Market SaleDirect | 24 | $758 | $18,196 | Form 4 ↗ |
| Oct 14, 2026 |
GrossPattern stores immutable raw artifacts, accession-scoped facts, parser and metric versions, dependency edges, quality state, and channel-specific publication rights. A restricted or unknown ancestor blocks the page and API automatically.
SEC source policy ↗Raw value 5.00% · OPTIONAL
Trade receivables changed +33.3% from the comparable as-filed period. The change ranks at the 100th percentile of 4 prior comparable changes.
Operating income changed +99.5% from the comparable as-filed period. This reverses 2 consecutive comparable moves in the opposite direction.
Free-cash-flow proxy changed -38.1% from the comparable as-filed period. This reverses 2 consecutive comparable moves in the opposite direction.
Operating margin changed +1269 basis points from the comparable as-filed period. This reverses 2 consecutive comparable moves in the opposite direction.
Current liabilities changed +40.2% from the comparable as-filed period. The change ranks at the 75th percentile of 4 prior comparable changes.
Trade receivables changed +17.0% from the comparable as-filed period. The change ranks at the 100th percentile of 4 prior comparable changes.
Method note “Materiality” here is an analytical magnitude band, not a legal conclusion. Full filing-text semantic changes remain unpublished while excerpt rights and review thresholds are unresolved.
Latest supported period in this snapshot: 2026-09-30. Duration facts use direct quarterly or annual SEC contexts; GrossPattern does not manufacture missing Q4 values.
0001238303-26-000002| MURPHY ANDREW JCo-Chief Scientific Officer |
| Open Market SaleDirect |
| 14 |
| $760 |
| $10,639 |
| Form 4 ↗ |
| Oct 14, 2026Filed Oct 15, 2026 | MURPHY ANDREW JCo-Chief Scientific Officer | Open Market SaleDirect | 74 | $761 | $56,288 | Form 4 ↗ |
| Oct 14, 2026Filed Oct 15, 2026 | MURPHY ANDREW JCo-Chief Scientific Officer | Open Market SaleDirect | 27 | $761 | $20,557 | Form 4 ↗ |
| Oct 14, 2026Filed Oct 15, 2026 | MURPHY ANDREW JCo-Chief Scientific Officer | Open Market SaleDirect | 55 | $763 | $41,941 | Form 4 ↗ |
| Oct 14, 2026Filed Oct 15, 2026 | MURPHY ANDREW JCo-Chief Scientific Officer | Open Market SaleDirect | 25 | $764 | $19,094 | Form 4 ↗ |
| Oct 14, 2026Filed Oct 15, 2026 | MURPHY ANDREW JCo-Chief Scientific Officer | Open Market SaleDirect | 219 | $764 | $167,404 | Form 4 ↗ |
| Oct 14, 2026Filed Oct 15, 2026 | MURPHY ANDREW JCo-Chief Scientific Officer | Open Market SaleDirect | 271 | $765 | $207,421 | Form 4 ↗ |
| Oct 14, 2026Filed Oct 15, 2026 | MURPHY ANDREW JCo-Chief Scientific Officer | Open Market SaleDirect | 279 | $766 | $213,845 | Form 4 ↗ |
| Oct 14, 2026Filed Oct 15, 2026 | MURPHY ANDREW JCo-Chief Scientific Officer | Open Market SaleDirect | 192 | $767 | $147,339 | Form 4 ↗ |
| Oct 14, 2026Filed Oct 15, 2026 | MURPHY ANDREW JCo-Chief Scientific Officer | Open Market SaleDirect | 105 | $768 | $80,675 | Form 4 ↗ |
| Oct 14, 2026Filed Oct 15, 2026 | MURPHY ANDREW JCo-Chief Scientific Officer | Open Market SaleDirect | 127 | $769 | $97,701 | Form 4 ↗ |
| Oct 14, 2026Filed Oct 15, 2026 | MURPHY ANDREW JCo-Chief Scientific Officer | Open Market SaleDirect | 12 | $770 | $9,242 | Form 4 ↗ |
| Oct 14, 2026Filed Oct 15, 2026 | MURPHY ANDREW JCo-Chief Scientific Officer | Open Market SaleDirect | 283 | $772 | $218,351 | Form 4 ↗ |
| Oct 14, 2026Filed Oct 15, 2026 | MURPHY ANDREW JCo-Chief Scientific Officer | Open Market SaleDirect | 211 | $773 | $163,010 | Form 4 ↗ |
| Oct 14, 2026Filed Oct 15, 2026 | MURPHY ANDREW JCo-Chief Scientific Officer | Open Market SaleDirect | 224 | $773 | $173,242 | Form 4 ↗ |
| Oct 14, 2026Filed Oct 15, 2026 | MURPHY ANDREW JCo-Chief Scientific Officer | Open Market SaleDirect | 121 | $774 | $93,712 | Form 4 ↗ |